Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,455 shares of the medical research company's stock after selling 629 shares during the period. Thermo Fisher Scientific accounts for approximately 0.8% of Arthur M. Cohen & Associates LLC's portfolio, making the stock its 25th biggest holding. Arthur M. Cohen & Associates LLC's holdings in Thermo Fisher Scientific were worth $4,207,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $25,000. Barrett & Company Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $28,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $30,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $3.63 during trading hours on Friday, reaching $401.99. 2,629,538 shares of the company traded hands, compared to its average volume of 1,905,224. The stock has a fifty day simple moving average of $422.35 and a 200 day simple moving average of $496.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The stock has a market capitalization of $151.75 billion, a PE ratio of 24.32, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.11 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TMO. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Royal Bank of Canada lowered their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.